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ABSTRACT 
Background & Aims - Metabolic syndrome (MetS), characterized by abdominal obesity, 
atherogenic dyslipidemia, elevated blood pressure, and insulin resistance is a major 
public health concern in the United States. The effect of Apolipoprotein E (Apo E) 
polymorphism has been relatively well studied in relation to cardiovascular disease; 
however, its effects on MetS are not well established.  
 
Methods - We conducted a cross-sectional study consisting of 1,551 participants from 
the National Heart, Lung, and Blood Institute (NHLBI) Family Heart Study to assess the 
relation of Apo E polymorphism with the prevalence of MetS. Information on the 
different Apo E genotypes was extracted from the database and we defined MetS 
according to the AHA-NHLBI-IDF-WHO Harmonized Criteria. We used generalized 
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estimating equations to estimate adjusted odds ratios for prevalent MetS and the 
Bonferroni correction to account for multiple testing in the secondary analysis.  
 
Results – Our study population had a mean age (SD) of 56.5 (11.0) years and 49.7% had 
MetS. There was no association between the Apo E genotypes and MetS. The 
multivariable adjusted ORs (95% CI) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-
1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the *e3/e3, *e2/e2, 
*e2/e3, *e2/e4, *e3/e4 and *e4/e4 genotype respectively. In a secondary analysis, the 
*e2/e3 genotype was associated with lower HDL levels, with the multivariable adjusted 
ORs (95% CI) of 0.59 (0.36-0.95) when compared to the reference *e3/e3 genotype.  
 
Conclusions - Our findings do not support an association between Apo E polymorphism 
and MetS in a multi-center population based study of predominantly white US men and 
women. The *e2/e3 genotype was associated with lower HDL levels as compared to the 
*e3/e3 genotype.  
 
Key words: Apolipoprotein E (Apo E) polymorphism, metabolic syndrome, blood 
pressure, glucose, waist circumference, triglycerides, high-density lipoprotein cholesterol  
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BACKGROUND 
(A) Metabolic Syndrome (MetS) 
A syndrome is a clustering of factors that occur together more often than by 
chance alone and for which the cause is often uncertain.1 According to the American 
Heart Association-National Heart, Lung, and Blood Institute-International Diabetes 
Federation-World Health Organization (AHA-NHLBI-IDF-WHO) Harmonized Criteria 
(2009), metabolic syndrome (MetS) is defined as having three or more of the following 
conditions: systolic blood pressure ≥ 130 mmHg and / or diastolic blood pressure ≥ 85 
mmHg or on antihypertensive therapy; fasting triglycerides ≥ 150 mg/dL or on 
triglyceride-lowering therapy; HDL cholesterol of less than 40 mg/dL for men and 50 
mg/dL for women or on drug therapy for low HDL cholesterol; fasting glucose of ≥ 100 
mg/dL or on antidiabetic therapy; and waist circumference of ≥ 102 cm in men, or ≥ 88 
cm in women, who are non-asians in the US.  
MetS has been a major public health concern in the United States for the past few 
decades and its prevalence has been increasing due to the increased rates of obesity. Ford 
et al. estimated that approximately 50 million U.S. adults in 1990 and approximately 65 
million in 2000 were diagnosed with MetS, representing a 28% increase in prevalence.2 
The US National Health Statistics Report showed that 34% of adults over 20 years of age 
from the National Health and Nutrition Examination Survey (NHANES) (2003-2006) had 
MetS.3  
Obesity is a major underlying risk factor for heart disease and type 2 diabetes, of 
which are also risk factors for MetS. Obesity is a multifaceted disease caused by an 
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imbalance between energy intake and energy expenditure, which in turn are affected by a 
multitude of environmental, social and cultural factors. Two major factors which 
contribute to the high prevalence are; plentiful supplies of inexpensive foods and 
sedentary lifestyles. With the advancement of technology, production of large quantities 
of inexpensive food is possible, while manual work is rapidly decreasing. It is a product 
of free society in which a multitude of food choices and job opportunities are available.4 
As a result, MetS is now both a public health and a clinical problem. In the public health 
arena, more attention must be given to modification of lifestyles of the general public to 
reduce obesity and to increase physical activity. At a clinical level, individual patients 
with MetS need to be identified so that their multiple risk factors, including lifestyle risk 
factors, can be reduced.3  
Patients with MetS are at twice the risk of developing coronary heart disease 
(CHD) over the next five to 10 years as compared to individuals without MetS because 
they are more prone to develop hypertension, hyperlipidemia and insulin resistance.4 
Furthermore, MetS confers a five-fold increase risk for type 2 diabetes mellitus.4 The 
most widely recognized metabolic risk factors of MetS are atherogenic dyslipidemia, 
elevated blood pressure, and elevated plasma glucose. Most of the individuals who 
exhibit these risks also have abdominal obesity and insulin resistance. In addition, they 
often manifest a prothrombotic state and a proinflammatory state.  
The first formalized definition of MetS was proposed by the WHO and 
International Diabetes Federation (IDF) in 1998.5 Insulin resistance was recognized as the 
major underlying risk factor for MetS. As such, evidence of insulin resistance was 
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required in addition to two additional risk factors, including obesity, hypertension, high 
triglyceride (TG) level, reduced high-density lipoprotein (HDL) cholesterol level, or 
microalbuminuria  by the IDF for the diagnosis of MetS,. The second recognized 
definition of MetS was established by the National Cholesterol Education Program’s 
Adult Treatment Panel III (ATP III) in 2001.6 The ATP III criteria did not require 
demonstration of insulin resistance and no single risk factor was required for diagnosis. 
Instead, the ATP III established that the presence of three of the following five factors 
were needed for the diagnosis of MetS: abdominal obesity (which is highly correlated 
with insulin resistance), elevated TG, reduced HDL cholesterol, elevated blood pressure, 
and/or elevated blood glucose (impaired fasting glucose or type two diabetes mellitus). In 
2005, both the International Diabetes Federation (IDF)7 and the American Heart 
Association / National Heart, Lung and Blood Institute (AHA/NHLBI)8 attempted to 
reconcile the different clinical definitions. The IDF eliminated the WHO requirement of 
insulin resistance but established that abdominal obesity (a surrogate for insulin 
resistance) should be recognized as one of five factors required in the diagnosis of MetS, 
(with particular emphasis on waist measurement as a simple screening tool); the 
remainder of the criteria were essentially identical to those provided by ATP III. 
Recently, IDF and AHA/NHLBI agreed that abdominal obesity need not be a prerequisite 
for diagnosis (of MetS), rather that it be one of five diagnostic criteria for MetS; the 
presence of any three of five risk factors constituting a diagnosis of MetS. The new 
harmonized definition is shown in Table 1. 
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Table 1: Criteria for Clinical Diagnosis of the Metabolic Syndrome4 
Measure Categorical Cut Points 
Elevated waist circumference Population and country specific 
definitions (Table 2) 
Elevated triglycerides (Drug treatment for 
elevated triglycerides as an alternate 
indicator*) 
≥150 mg/dL (1.7 mmol/L) 
Reduced high-density lipoprotein cholesterol 
(Drug treatment for reduced HDL cholesterol 
is an alternate indicator*) 
Males: <40 mg/dL (1.0 mmol/L) 
Females: <50 mg/dL (1.3 mmol/L) 
Elevated blood pressure (Antihypertensive 
drug treatment in a patient with a history of 
hypertension is an alternate indicator) 
Systolic ≥130 and / or 
Diastolic ≥85 mm Hg 
Elevated fasting glucose (Drug treatment of 
elevated glucose is an alternate indicator) 
≥100 mg/dL (5.6 mmol/L) 
* The most commonly used drugs for elevated TG and reduced HDL cholesterol are 
fibrates and nicotinic acid. A patient taking one of these drugs can be presumed to have 
high triglycerides and low HDL cholesterol 
Obesity is defined as an excess of body fat. A surrogate marker for body fat 
content is the body mass index (BMI), which is determined by weight (kilograms) 
divided by height squared (square meters). Individuals with a BMI of 25-29 kg/m2 are 
referred to as overweight, while those with higher BMIs of ≥ 30 kg/m2 are considered 
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obese.9 In clinical practice, the best way to estimate obesity is to measure waist 
circumference.10 This is because excess abdominal fat is highly associated with the 
metabolic risk factors.11 In the United States, abdominal obesity is defined as a waist 
circumference of ≥102cm in men and ≥88cm in women. In other countries, different 
thresholds are used depending on ethnic groups (Table 2). Abdominal fat is located in 
two major compartments; subcutaneously (SC) and intraperitoneal (IP) (viscerally).5, 11, 12 
Several terms have been used to describe excess fat in the trunk: abdominal obesity, 
truncal obesity and upper body obesity. In fact, there is a strong correlation between waist 
circumference and upper body fat content. Therefore, because an increased girth is most 
readily recognized clinically, the term “abdominal obesity” is widely used in clinical 
practice.5, 6 
Defining thresholds for abdominal obesity is complicated, in part because of 
differences in the relation of abdominal obesity to other metabolic risk factors. In 
addition, predictive values for various levels of abdominal obesity for CHD and diabetes 
may differ. Table 2 shows current international recommendations proposed by the 
various organizations. 
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Table 2: Current Recommended Waist Circumference Thresholds for Abdominal 
Obesity by Organization4 
Recommended Waist 
Circumference Threshold for 
Abdominal Obesity	  
Population Organization (Reference) 
Men Women 
Europid IDF (8) ≥ 94 cm	   ≥ 80 cm	  
Caucasian 
WHO (13) 
≥ 94 cm 
(increased risk) 
≥ 102 cm 
(still higher risk)	  
≥ 80 cm 
(increased risk) 
≥ 88 cm 
(still higher risk)	  
United States AHA/NHLBI (ATP III) (10) ≥ 102 cm	   ≥ 88 cm 	  
Canada Health Canada (14, 15)  ≥ 102 cm	   ≥ 88 cm	  
European European Cardiovascular 
Societies (16) 
≥ 102 cm ≥ 88 cm 
Asian (including Japanese) IDF (8) ≥ 90 cm ≥ 80 cm 
Asian WHO (17) ≥ 90 cm ≥ 80 cm 
Japanese Japanese Obesity Society (18) ≥ 85 cm ≥ 90 cm 
China Cooperative Task Force (19) ≥ 85 cm ≥ 80 cm 
Middle East, Mediterranean IDF (8) ≥ 94 cm ≥ 80 cm 
Sub-Saharan African IDF (8) ≥ 94 cm ≥ 80 cm 
Ethnic Central and South 
American 
IDF (8) ≥ 90 cm  ≥ 80 cm  
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Atherogenic dyslipidemia is characterized by an increase in TG, increased very 
low-density lipoprotein (VLDL) particles, increased small LDL particles and low HDL 
cholesterol.6 The increased number of VLDL and LDL particles accounts for the 
increased level of total apolipoprotein B usually observed with atherogenic dyslipidemia. 
The LDL particles associated with MetS and atherogenic dyslipidemia tend to be small 
and dense. A theory widely held is that smaller LDL particles are more atherogenic than 
larger LDLs because they filter more readily into the arterial wall, therefore, are more 
prone to atherogenic modification.20 A simple strategy for assessing the sum of 
atherogenic particles is measurement of either LDL and VLDL cholesterol (non-HDL 
cholesterol), or total apolipoprotein B.6 Individuals with MetS and atherogenic 
dyslipidemia usually have elevated LDL, VLDL and total apolipoprotein B. These 
measurements are being used increasingly both in risk assessment and as targets of 
therapy in patients with MetS.21  Another typical characteristic of atherogenic 
dyslipidemia is a low HDL level. As a risk predictor, a low HDL rivals an elevated total 
apolipoprotein B or VLDL and LDL cholesterol. This has led to the concept that HDL is 
intimately involved in the atherogenic process. Some of the suggested mechanisms 
whereby HDL is antiatherogenic include enhanced reverse cholesterol transport 
capabilities, its anti-inflammatory properties and its ability to protect against LDL 
modification. Obesity itself reduces HDL levels because of the enhancement in the 
uptake of HDL by adipocytes, therefore obese patients with MetS and atherogenic 
dyslipidemia almost always have low HDL levels. Thus, the association between low 
HDL and atherosclerotic cardiovascular disease (CVD) is complex, and the various 
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components of this association are difficult to differentiate. However, the presence of a 
low HDL level remains a strong predictive factor for the development of atherosclerotic 
CVD, regardless of the mechanisms.  
Elevated blood pressure is strongly associated with obesity, commonly occurs in 
insulin-resistant individuals, and is a known risk factor in the diagnosis of MetS.  One of 
the possible mechanisms is increased vascular tone, created by a reduced bioavailability 
of nitric oxide (NO) because of increased oxidative stress22 and increased concentrations 
of asymmetric dimethylarginine (ADMA) -an endogenous inhibitor of nitric oxide 
synthase.23 Elevated blood pressure is also a strong risk factor for cardiovascular disease 
(CVD). Well-known complications of elevated blood pressure are CHD, stroke, left 
ventricular hypertrophy, heart failure, and chronic renal failure.  
Diabetes - Epidemiological studies have proven that the onset of diabetes is 
accompanied by increased risk for atherosclerotic CVD, suggesting that elevated plasma 
glucose or hyperglycemia per se is atherogenic. A variety of mechanisms have been 
proposed whereby elevated plasma glucose might promote atherosclerosis. Examples 
include nonenzymatic glycosylation of lipids and proteins; pathogenic effects of 
advanced glycation products; increased oxidative stress; activation of protein kinase C, 
and microvascular disease of the vasa vasorum of the coronary arteries.24 Atherosclerosis 
and diabetes are risk factors that are closely associated with MetS.  
A proinflammatory state, defined clinically by elevated levels of C-reactive 
protein (CRP) is commonly present in patients with MetS. The basic concept is that 
atherogenesis represents a state of chronic inflammation. It is characterized by lipid-
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induced injury that initiates invasion of macrophages followed by proliferation of smooth 
muscle cells. The finding that elevations of serum CRP carry predictive power for the 
development of major cardiovascular events led to the concept that advanced and 
unstable atherosclerotic plagues are in an even higher state of inflammation than stable 
plagues.25 Studies have reported that obese persons26 and particularly those with MetS27 
have elevated levels of CRP. These findings have suggested that obesity is a 
proinflammatory state and is connected with the development of unstable atherosclerotic 
plaques.  
Obesity is accompanied by a larger number of coagulation and fibrinolytic 
abnormalities.28 This suggests that obesity induces a prothrombotic state. It is highly 
likely that the obesity induced procoagulant and antifibrinolytic factors contribute to a 
worsening of acute coronary syndromes. Thrombosis occurring with plaque rapture or 
erosion is a key element in determining the severity of the syndrome. If normal 
coagulation and fibrinolysis are impaired at the time of plaque rapture or erosion, then a 
larger thrombus is formed, which may lead to the occurrence of a significant acute 
coronary syndrome event. If that is the case, then the presence of a prothrombotic state is 
important for determining the clinical outcome of the severity of the cardiac event.  
 
 (B) Apolipoprotein E (ApoE) Gene 
The ApoE gene is located on the long (q) arm of chromosome 19 at position 13.2. 
It is polymorphic with three common alleles, *e2, *e3 and *e4, producing three isoforms 
of the protein; E2, E3 and E4. Apo E3 contains cysteine at position 112 and arginine at 
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158. Apo E2 has cysteine and E4 has arginine at both sites respectively.29 Despite this 
single amino acid substitution, they result in profound functional consequences at both 
the molecular and cellular levels.30 While there are rare variants, it is the *e2, *e3 and 
*e4 alleles polymorphism that has been studied in relation to cardiovascular disease. The 
six most common phenotypes, ranking from most to least common are E3/3, E4/3, E3/2, 
E4/4, E4/2 and E2/2.31 The *e3 is the most common allele, and approximately 60% of 
North Americans are homozygous for this genetic variant.32 The prevalence of the *e4 
allele is about 13% in the predominantly white Caucasian population in the Framingham 
Heart Study.33  
The various ApoE isoforms interact differently with specific lipoprotein receptors, 
ultimately altering circulating levels of cholesterol. ApoE from VLDL, chylomicrons, 
and chylomicron remnants binds to specific receptor cells in the liver. Carriers of the *e2 
allele are less efficient at making and transferring VLDLs and chylomicrons from the 
blood plasma to the liver because of its binding properties. In contrast, carriers of the *e3 
and *4 alleles are much more efficient in this processes. While ApoE4 and E3 bind with 
approximately equal affinity to lipoprotein receptors, ApoE2 binds with less than 2 
percent of this strength.34 Therefore, carriers of the *e2 allele are slower to clear dietary 
fat from their blood.35 The difference in uptake of postprandial lipoprotein particles 
results in differences in regulating hepatic low-density lipoprotein (LDL) receptors, 
which in turn contributes to the differences in the total and LDL cholesterol levels.36, 37  
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(C) Role of ApoE Polymorphism in CHD and Type 2 Diabetes Mellitus 
Polymorphism is defined as a genetic variant at a single location within a gene, 
and must be present in at least one percent of a population. Candidate polymorphism 
studies typically rely on prior scientific evidence suggesting that the set of 
polymorphisms under investigation is relevant to the disease trait. The aim is to test for 
the presence of association, and the primary hypothesis is that the variable site under 
investigation is functional, and whether it influences the phenotype of the disease trait.  
ApoE is one of the most thoroughly studied gene; especially for its effects on lipid 
profiles and CHD risk. The homozygous *e3/3 genotype is usually used as the reference 
to determine the risk in comparison to other genotypes. Generally, *e2 lowers total 
cholesterol levels 2-3 times more than that of the *e4 cholesterol-raising effect. Hallman 
et al reported that the *e2 lowers cholesterol levels by approximately 14mg/dL while *e4 
raises the levels by approximately 8mg/dL.36  
 Epidemiological studies have investigated the direct impact of ApoE on CHD, as 
well as its impact on cholesterol levels. One study of middle-aged men from nine 
populations estimated an approximately 40 percent increased risk for CHD mortality for 
*e4 carriers compared with *e3/3 genotype or *e2 carriers.38  Other studies have reported 
that *e4 carriers are more prone to develop disseminated coronary lesions and have an 
increased risk of death from CHD.39, 40, 41, 42 Studies from Finland, Scotland and northern 
Ireland have shown that populations with higher cholesterol levels and higher CHD 
mortality rates also have a higher frequency of the *e4 allele.43 The Monitoring of Trends 
and Determinants in Cardiovascular Disease (MONICA) project is a multinational study 
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sponsored by the World Health Organization, which monitored the trends in 
cardiovascular mortality and morbidity and assessed the relation of these trends to 
changes in risk factors or medical care. The results from this study showed that the CHD 
mortality rate increased by 24.5/100,000 for an increase of 0.01 in the relative frequency 
of the *e4 allele.37  
ApoE polymorphism was also investigated in type 2 diabetes mellitus (T2DM) in 
the recent years. Insulin resistance is strongly associated with metabolic dyslipidemia and 
the correlation of lipid profiles with diabetic phenotypes is important, since T2DM 
patients have an atherogenic lipid profile, which greatly increases their risk of CHD 
compared to people without diabetes. A meta-analysis conducted by Anthopoulos et al 
reported that ApoE2 was a moderate risk factor for T2DM.44 However, further studies are 
needed in order to elucidate the metabolic mechanism of this association.  
The significant impact of ApoE polymorphism in T2DM, total cholesterol, TG 
and LDL metabolism implies that determination of the ApoE genotypes maybe a useful 
adjunct to the assessment of the MetS profile of an individual. However, the association 
between ApoE polymorphism and MetS has not been well defined. This study will 
attempt for the first time, to determine the association of ApoE polymorphisms and MetS 
in a predominantly Caucasian population.  
 
THESIS STATEMENT 
The primary objective of this study was to determine the association of Apo E 
polymorphism with the prevalence of MetS. The secondary objective was to determine 
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the association of Apo E polymorphism with the individual components (blood pressure, 
glucose, HDL, TG and waist circumference) of MetS. This is a cross-sectional study 
consisting of 1,551 participants from the National Heart, Lung, and Blood Institute 
(NHLBI) Family Heart Study.  
 
MATERIALS & METHODS 
(A) Study Population45 
The NHLBI Family Heart Study is a multicenter, population-based study of 
genetic and non-genetic determinants of CHD, atherosclerosis and cardiovascular risk 
factors in individuals and families recruited from existing population-based studies 
(parent studies).  
In phase I, 2,000 randomly selected participants and 2,000 participants with 
family histories of CHD were identified from the 14,592 middle-aged participants in 
three epidemiologic studies, including the Framingham Heart Study in Massachusetts, the 
Atherosclerosis Risk in Communities (ARIC) Study in Minnesota and North Carolina, 
and the Utah Health Family Tree Study in Utah. Medical histories from each participant, 
their parents and siblings were collected. This information was used to calculate family 
risk scores that compared the number of reported and validated CHD events with the 
number expected based on the size, sex, and age of the family members.  
In phase II, a total of 657 families with the highest risk scores and early-onset of 
CHD and 588 randomly sampled families had clinic examinations that included 
electrocardiograms, carotid artery ultrasound scans, spirometry, measurement of body 
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size, blood pressure, lipids, lipoproteins, hemostatic factors, insulin, glucose, and other 
routine chemistries. All study participants were asked to fast for 12 hours before coming 
to the clinic and to bring their medications with them. Names, doses and frequency of use 
of prescribed and over-the-counter medications used in the 2 weeks prior to examination 
were recorded and coded. Information on cigarette smoking and alcohol intake was 
obtained by interview during clinic visits. The amount of exercise was obtained through 
self-reports. Additional biochemical and genetic studies, including Apolipoprotein A, 
Apolipoprotein B, Apolipoprotein E, Factor V, angiotensin-converting enzyme and 
angiotensinogen were performed on selected participants. Serum, plasma and DNA were 
stored for future studies, which included genotyping of candidate genes and anonymous 
markers. The study was carried out at 4 different geographical sites, which included 
Forsyth County (North Carolina), Minneapolis (Minnesota), Framingham 
(Massachusetts) and Salt Lake City (Utah).  
 
(B) Laboratory Assays46 
All laboratory assays were collected when the parent study was carried out. ApoE 
genotyping was performed using Polymerase Chain Reaction (PCR) to amplify a 267 bp 
fragment from exon three of the ApoE gene.  
Cholesterol was measured using a commercial cholesterol oxidase method on a 
Roche COBAS FARA centrifugal analyzer (Boehringer Mannheim Diagnostics, 
Indianapolis, IN 46250).  
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Triglyceride was measured using Triglyceride GB reagent on the Roche COBAS 
FARA centrifugal analyzer (Boehringer Mannheim Corp., Indianapolis, IN 46250-0457). 
LDL-cholesterol quantitation was performed on EDTA plasma by 
ultracentrifugation using a Beckman TLA 100 table top ultracentrifuge with a Beckman 
TLA 100.3 fixed angle rotor (Beckman, Brea, CA 92621-6209). The LDL-cholesterol 
was calculated as the difference between the measured cholesterol in the volume-adjusted 
infranate times two minus the HDL-cholesterol measured in the original plasma. For 
samples with triglyceride levels less than 400 mg/dL, LDL-cholesterol was calculated 
using the Friedwald formula. 
Glucose was measured by a thin film adaptation of a glucose oxidase enzymatic, 
spectrophotometric procedure using the Vitros analyzer (Johnson & Johnson Clinical 
Diagnostics, Inc. Rochester NY). 
 
(C) Cross-sectional Study 
In the current cross-sectional study, data on 1,551 participants were analyzed. The 
original cohort consisted of 5,975 participants, however because of missing data for 
ApoE (n=4225), metabolic syndrome criteria or covariates (n=199), 1,551 participants 
were used in analysis. MetS was defined using the AHA-NHLBI-IDF-WHO Harmonized 
Criteria (2009) as having three or more of the following conditions:  
• Systolic blood pressure ≥ 130 mmHg and / or diastolic blood pressure ≥ 85 
mmHg or on antihypertensive therapy;  
• Fasting triglycerides ≥ 150 mg/dL or on triglyceride-lowering therapy;  
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• HDL cholesterol of less than 40 mg/dL for men and 50 mg/dL for women or on 
drug therapy for low HDL cholesterol;  
• Fasting glucose of ≥ 100 mg/dL or on antidiabetic therapy; and  
• Waist circumference of ≥ 102 cm in men, or ≥ 88 cm in women.  
The following information was extracted from the existing database: 
• ApoE genotypes  
• Baseline demographics (including age, sex and race)  
• Field centers  
• Cigarette smoking  
• Alcohol consumption  
• Exercise status 
 
STATISTICAL ANALYSIS  
Apo E was categorized according to the various genotypes and the most common 
group, *e3/e3, was used as the reference. Baseline characteristics were presented 
according to Apo E genotypes and compared using ANOVA.  
To correct for familial clustering, generalized estimating equations (GEE) was 
used to calculate the prevalence odds ratios and 95% confidence intervals (CIs) for the 
presence of metabolic syndrome across the different Apo E genotypes. GEE accounts for 
correlation matrix among related individuals. Confounding was assessed for age, gender 
(male/female), race (Caucasian/African American/other), current drinker (yes/no), current 
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smoker (yes/no), exercise (quartiles), and field center (Forsyth, NC/Minneapolis, 
MN/Framingham, MA/ Salt Lake, UT).  
In a secondary analysis, the above analysis was repeated for individual 
components of MetS according to the AHA-NHLBI-IDF-WHO Harmonized Criteria 
definition.1 The Bonferroni Correction was used to account for multiple testing. All p-
values are two-tailed and significance was set at an alpha of 0.05 (0.01 with Bonferroni 
correction for five exposures in secondary analysis). All analyses were performed using 
SAS version 9.2 (SAS institute Inc, Cary, NC).  
 
RESULTS 
 Table 1 represents baseline characteristics of our study participants according to 
Apo E genotypes. The mean age (SD) of the sample was 56.5 (11.0) years and the 
prevalence of MetS was 49.7%.  
 Table 2 shows frequencies of ApoE genotypes distribution among study 
participants, with or without MetS. The most frequent genotype in the sample was 
*e3/e3, followed by *e4/e3, *e3/e2, *e4/e4, *e4/e2, and *e2/e2. There was no significant 
association between ApoE genotypes and prevalence of MetS. Adjustment for age, 
gender, field center, alcohol consumption, smoking and exercise did not alter the results 
in Table 2.   
 As shown in Table 3, in multivariable adjusted generalized estimating equations, 
there were no significant associations between blood pressure, glucose, triglycerides and 
waist circumference with ApoE genotype. Compared to subjects with the *e3/3 genotype, 
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individuals with the *e2/3 genotype were more likely to have lower HDL levels (p-
value=0.005).  
 
DISCUSSION 
In this cross-sectional study, no association between ApoE polymorphism and 
prevalence of MetS was found. This study is the first in a predominantly white 
population. In a recent study of young Asian Indian patients with acute myocardial 
infarction, none of the ApoE alleles was associated with a higher prevalence of MetS.47 
In contrast, Tao et al. reported that the *e4 allele was associated with a significantly 
increased risk of MetS in an elderly Chinese male population.48 The *e4 allele was also 
reported to be associated with a significantly increased risk of MetS in an Italian 
population with cardiovascular disease, but these subjects were non-diabetics and not on 
lipid-lowering therapy.49 In a Romanian study, the investigators reported that the 
frequency of the *e4 allele was higher in the MetS group compared to those without 
MetS.50 However, the *e4 allele was inversely associated with the prevalence of MetS in 
an extremely obese Brazilian population.51 
One important factor to consider is the definition of MetS. All the studies above 
used either the NCEP ATP III or IDF definition. However, the new AHA-NHLBI-IDF-
WHO Harmonized Criteria (2009) was used in this study. This new criteria are more 
stringent than the ATP III or IDF definition because drug therapy (anti-hypertensives, 
lipid-lowering therapy and anti-diabetics) was taken into consideration. It is highly 
possible that certain study participants in the above-mentioned studies had well-
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controlled blood pressure, glucose, LDL and HDL levels because of their drug therapy; 
but were categorized in the non-MetS group because drug therapy was not part of the 
definition.  
 In the secondary analysis, an inverse correlation was observed between the *e2/e3 
genotype and HDL levels. One study reported that the Apo E2 decreased HDL 
cholesterol by 3.1% as compared with the Apo E3.52 The suggested mechanism was that 
the ApoE2 isoform preferentially binds to the smaller, phospholipid-rich HDL 
cholesterol.53 However, a meta-analysis showed a slight increase of HDL levels in the 
*e2/e3 genotype.54 One of the possible reasons for the discrepancy with this study’s 
results is the difference in lipid lowering therapy. At baseline, the percentage of lipid 
lowering therapy in the *e2/e3 group was approximately 5% lower than the *e3/e3 group 
(11.6% vs 16.8% respectively), and was the lowest across the genotype groups. Lipid 
lowering therapy has been proven to increase HDL cholesterol - Nicotinic acid by 15-
35%; fibrates by 10-35%; and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) 
Reductase Inhibitors by 5-15%.6 Therefore, it is possible that those in the *e3/e3 group 
had a relatively higher HDL level because of the effects of therapies.  
The prevalence of MetS in this study was 49.7%, which is approximately 16% 
higher than the 2009 US National Health Statistics Report. The US National Health 
Statistics Report used the NECP ATP III revised guidelines, of which only anti-
hypertensives and anti-diabetics were accounted for. However, the new AHA-NHLBI-
IDF-WHO Harmonized Criteria was used in our study, of which lipid-lowering therapy 
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was also accounted for, and this could have possibly led to the higher prevalence of MetS 
observed.   
The most frequent genotype in this study population was *e3/e3, followed by 
*e4/e3, *e3/e2, *e4/e4, *e4/e2, and *e2/e2. This allelic distribution was consistent with 
the results from other studies.30, 55 This is important because it implies that both the allele 
and genotype frequencies in this study population remain constant, and are in equilibrium 
from generation to generation, therefore fulfilling the Hardy-Weinberg principle. The 
Hardy-Weinberg Equilibrium (HWE) principle has the following five main assumptions 
that should be fulfilled:  
• Mutation is not occurring (alleles does not change) 
• Natural selection is not occurring (Natural selection may increase the 
frequencies of alleles if they are advantageous to survival, therefore leading to 
an evolutionary change in the genetic composition of a population)   
• The population is infinitely large (a small population size can cause a random 
change in allele frequencies) 
• All mating is random 
• There is no migration in or out of the population (no exchange of alleles 
between different populations) 
Apo E polymorphism as a predictor of cardiovascular disease has been well 
studied over the years. In 2007, a meta-analysis published by Bennet et al. summarized 
the evidence from 147 studies on the association of Apo E genotypes with lipid levels 
and cardiac risk.53 Eighty-two studies included data on the association of Apo E with 
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lipid levels, and 121 studies reported the association with clinical outcomes. The authors 
reported that patients with the *e2/e2 genotype had LDL levels that were approximately 
31% less compared with the *e4/e4 genotype. There were approximate linear 
relationships of Apo E genotypes (when ordered *e2/e2, *e2/e3, *e2/e4, *e3/e3, *e3/e4, 
*e4/e4) with LDL levels and coronary risk. The relationship with HDL cholesterol was 
inverse and shallow, and that with TG was nonlinear and largely confined to the *e2/e2 
genotype. Compared with individuals with the *e3/e3 genotype, *e2 carriers had a 20% 
lower risk of coronary heart disease while *e4 carriers had a slightly higher risk.  
 Despite this evidence, no clinical practice guidelines or US professional 
associations (American Heart Association / US Preventive Services Task Force / National 
Cholesterol Education Program Expert Panel / American Diabetes Association) have 
recommended the use of Apo E genotyping in cardiovascular risk assessment. One of the 
possible reasons is that while Apo E genotypes may be associated with lipid levels and 
CHD, it is a relatively poor predictor of CHD and is unlikely to provide additional 
clinically relevant information beyond traditional lipid measures such as LDL. 
Furthermore, no studies comparing the clinical outcomes of patient management based on 
Apo E genotypes with patient management based on conventional risk assessment 
measures such as LDL have been performed.  
 Likewise, while preliminary finding from this study is unlikely to change clinical 
practices at the moment, it serves as a catalyst for future studies to further explore the 
role of Apo E in metabolic syndrome.  
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STUDY LIMITATIONS & STRENGTHS 
One of the study limitations was the inability to determine causal relation between 
Apo E polymorphism and MetS because of the cross-sectional study design. Although the 
causal relation could not be determined, the genetic makeup of each individual does not 
change over time, therefore the estimates of association was expected to be relatively 
reliable. The Hardy-Weinberg equilibrium of the genotypes was not tested because some 
of the study participants in the Family Heart Study were related to one another. However, 
when compared to other studies, the Apo E allele frequency distribution in our study was 
similar, indicating that the Hardy-Weinberg equilibrium might be fulfilled in our study. 
According to the AHA-NHLBI-IDF-WHO Harmonized Criteria, the most commonly 
used drugs for elevated triglycerides and reduced HDL-C were fibrates and nicotinic 
acid; patients taking one of these drugs were presumed to have high TG and low HDL-C. 
However, in this study the specific type of lipid lowering therapy the participants were 
prescribed was not available for analysis. To date, this is the largest and the only multi-
center, population-based study assessing the relationship between ApoE polymorphism 
with prevalent MetS in a predominantly white population. The relatively large sample 
size of study participants was a strength of this study. Adjustments were made for 
environmental and behavioral factors that might affect the phenotype independently of 
the genes of interest, which increased the accuracy of these results.  
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CONCLUSION 
These findings do not support an association between Apo E polymorphism and 
MetS in this multi-center population-based study of predominantly white US men and 
women.  
In our secondary analysis, there was no association between Apo E polymorphism 
and MetS with blood pressure, glucose levels, triglycerides and waist circumference. The 
*e2/e3 genotype was associated with lower HDL levels as compared to the *e3/e3 group.  
 
FUTURE STUDIES  
The association between Apo E polymorphism and MetS may be further explored 
in longitudinal studies, eg. Framingham Heart Study, looking at whether the onset of 
MetS has any association with certain Apo E genotypes. In addition, the role of Apo E in 
MetS can also be compared between men and women. Prospective cohorts or randomized 
controlled trials comparing the health outcomes of patient management based on Apo E 
genotypes with patient management based on conventional metabolic risk assessment 
measures can also be carried out.  
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TABLES 
Table 3. Baseline characteristics of 1551 subjects in the NHLBI Family Heart Study by 
Apolipoprotein E genotypes1 
Variables Apolipoprotein E Genotypes 
 
*e3/e3  
(n=900) 
*e2/e2 
(n=8) 
*e2/e3 
(n=168) 
*e2/e4 
(n=38) 
*e3/e4 
(n=395) 
*e4/e4 
(n=42) 
Age (y) 56.8±11.1 65.3±6.1 57.8±11.1 59.6±8.2 54.9±10.7 53.8±12.0 
Body mass 
index (kg/m2) 
28.4±5.7 30.0±4.6 28.6±5.8 28.9±3.4 28.3±5.4 29.1±5.7 
Waist 
Circumference 
(cm) 
100.1±14.7 107.0±12.6 100.2±16.1 101.6±9.9 99.2±15.1 100.0±14.2 
TG (mg/dL) 161.9±106.3 
241.1 
±164.6 
168.6 
±122.5 
188.6 
±135.7 
172.4 
±101.0 
181.8±84.4 
LDL (mg/dL) 131.6±34.7 83.3±34.9 114.0±31.3 
116.1±31.
2 
132.4±36.
1 
136.7±38.9 
HDL (mg/dL) 49.1±15.9 44.8±11.6 52.0±16.1 46.9±14.9 46.3±14.0 45.6±11.9 
Exercise 
(min/day) 
28.4±34.5 14.5±20.0 27.2±33.7 20.8±23.2 26.5±42.9 35.7±63.3 
Males 47.0 50.0 45.2 57.9 48.1 50.0 
Race & 
Ethnicity 
  
Non-Hispanic  
      White 
98.0 100.0 95.2 100.0 93.2 92.9 
African 1.56 0.0 3.6 0.0 5.6 7.1 
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American 
Others 0.4 0.0 1.2 0.0 1.3 0.0 
       
Hypertension 37.4 50.0 33.3 47.4 30.1 40.5 
Diabetes 9.6 25.0 11.3 7.9 8.6 2.4 
Coronary Heart 
Disease 
19.0 12.5 14.9 21.1 19.0 21.4 
Current Smoker 13.8 12.5 14.9 10.5 13.2 21.4 
Current Drinker 48.9 62.5 48.2 60.5 48.6 50.0 
1Data are presented as means (±) SD or percentages 	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Table 4. Prevalence odds ratios (95% confidence intervals) of metabolic syndrome 
according to Apolipoprotein E genotypes 
Apolipoprotein 
E Genotypes 
MetS cases / N Crude  
Adjusted  
Model 1* 
Adjusted  
Model 2† 
*e3/e3  440/900 1.00 (ref) 1.00 (ref) 1.00 (ref) 
*e2/e2 5/8 1.74 (0.41-7.35) 1.28 (0.31-5.27) 1.26 (0.31-5.21) 
*e2/e3 79/168 0.93 (0.65-1.32) 0.90 (0.63-1.29) 0.89 (0.62-1.29) 
*e2/e4 21/38 1.29 (0.70-2.39) 1.16 (0.62-2.15) 1.13 (0.61-2.10) 
*e3/e4 199/395 1.06 (0.82-1.38) 1.15 (0.90-1.49) 1.13 (0.88-1.47) 
*e4/e4 26/42 1.70 (0.88-3.27) 1.94 (0.94-3.98) 1.87 (0.91-3.85) 
* Adjusted for age, gender, race using generalized estimating equations (GEE) 
† Adjusted for age, gender, race, field center (Forsyth/ Minneapolis/ Framingham/ Salt 
Lake), alcohol intake (yes/no), smoking (yes/no), exercise (quartiles) using generalized 
estimating equations (GEE) 	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Table 5. Prevalence odds ratios (99% confidence intervals) of individual components of 
metabolic syndrome according to Apolipoprotein E genotypes  
 
Apolipoprotein 
E Genotypes 
Blood 
pressure 
Glucose Triglycerides 
High-density 
lipoprotein  
Waist 
Circumference 
Crude Model 
*e3/e3  1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
*e2/e2 
2.07  
(0.31-13.74) 
4.69  
(0.57-38.79) 
1.62  
(0.24-10.75) 
1.42  
(0.21-9.40) 
2.18  
(0.26-18.04) 
*e2/e3 
1.10  
(0.67-1.81) 
0.76  
(0.46-1.26) 
0.86  
(0.54-1.39) 
0.59  
(0.37-0.95) 
1.10  
(0.68-1.76) 
*e2/e4 
1.12  
(0.43-2.88) 
1.02  
(0.42-2.49) 
1.20  
(0.55-2.62) 
1.05  
(0.41-2.72) 
2.04  
(0.81-5.11) 
*e3/e4 
0.68  
(0.48-0.98) 
0.76  
(0.54-1.07) 
1.33  
(0.93-1.90) 
1.35  
(0.98-1.85) 
0.90  
(0.64-1.28) 
*e4/e4 
0.93  
(0.36-2.40) 
0.96  
(0.32-2.86) 
1.75  
(0.72-4.29) 
1.70  
(0.75-3.84) 
1.07  
(0.44-2.61) 
Adjusted Model 1* 
*e3/e3  1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
*e2/e2 
1.16  
(0.23-6.03) 
3.46 
(0.41-29.43) 
1.41  
(0.20-9.73) 
1.47  
(0.21-10.51) 
1.96  
(0.29-13.06) 
*e2/e3 
1.02  
(0.56-1.86) 
0.72  
(0.44-1.18) 
0.88  
(0.54-1.41) 
0.61  
(0.38-0.97) 
1.06  
(0.64-1.76) 
*e2/e4 
0.92  
(0.34-2.49) 
0.88  
(0.35-2.22) 
1.11  
(0.51-2.42) 
1.01  
(0.38-2.68) 
2.21  
(0.90-5.43) 
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*e3/e4 
0.72  
(0.50-1.04) 
0.79  
(0.55-1.11) 
1.44  
(1.00-2.05) 
1.38  
(1.00-1.90) 
0.94  
(0.66-1.34) 
*e4/e4 
1.05  
(0.39-2.86) 
1.03  
(0.36-2.94) 
1.94  
(0.75-5.01) 
1.71  
(0.74-3.97) 
1.17  
(0.44-3.12) 
Adjusted Model 2† 
*e3/e3  1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
*e2/e2 
1.15  
(0.23-5.73) 
3.45  
(0.40-29.41) 
1.37  
(0.21-8.84) 
1.44  
(0.24-8.82) 
1.78  
(0.23-13.99) 
*e2/e3 
1.04  
(0.57-1.90) 
0.73  
(0.44-1.21) 
0.86  
(0.53-1.40) 
0.59  
(0.36-0.95) 
1.04  
(0.61-1.78) 
*e2/e4 
0.89  
(0.34-2.35) 
0.82  
(0.33-2.04) 
1.08 
 (0.50-2.33) 
1.02 
 (0.42-2.50) 
2.10  
(0.85-5.16) 
*e3/e4 
0.72  
(0.49-1.05) 
0.79  
(0.55-1.12) 
1.41  
(0.98-2.02) 
1.38  
(0.99-1.92) 
0.91  
(0.64-1.29) 
*e4/e4 
1.05  
(0.39-2.87) 
0.96  
(0.33-2.79) 
1.92  
(0.92-3.99) 
1.65  
(0.70-3.91) 
1.19  
(0.47-2.99) 
* Adjusted for age, gender, race using generalized estimating equations (GEE) 
† Adjusted for age, gender, race, field center (Forsyth/ Minneapolis/ Framingham/ Salt 
Lake), alcohol intake (yes/no), smoking (yes/no), exercise (quartiles) using generalized 
estimating equations (GEE) 	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LIST OF JOURNAL ABBREVIATIONS 
 
Abbreviations Full Text  
Am J Cardiol American journal of cardiology 
Am J Hum Genet American journal of human genetics 
Am J Epidemiol American journal of epidemiology 
Annu Rev Genomics Hum 
Genet 
Annual review of genomics and human genetics 
Arterioscler Thromb Arteriosclerosis and Thrombosis: a journal of 
vascular biology / American Heart Association 
Arterioscler Thromb Vasc Biol Arteriosclerosis, thrombosis, and vascular biology 
Biol Chem The Journal of biological chemistry 
Can J Cardiol The Canadian journal of cardiology 
Cardiovasc Diabetol Cardiovascular diabetology 
Circ J Japanese circulation journal 
Clin Chem Clinical chemistry 
Clin Chem Lab Med Clinical chemistry and laboratory medicine 
Clinica Chimica Acta Clinica chimica acta; International journal of 
clinical chemistry 
Clin Exp Med International journal of clinical and experimental 
medicine 
Diabet Med Diabetic medicine: a journal of the British 
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Diabetic Association 
Diabetes Res Clin Pract Diabetes research and clinical practice 
JAMA The journal of the American Medical Association 
J Am Coll Cardiol Journal of the American College of Cardiology 
J Clin Endocrinol Metab The Journal of clinical endocrinology and 
metabolism 
J Clin Invest The Journal of clinical investigation 
J Endocrinol Invest Journal of endocrinological investigation 
Metab Syndr Relat Disord Metabolic syndrome and related disorders 
Obes Res Obesity research 
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